Search
RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change
He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are...
May 21, 2025
ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development
As published in NEJM today , UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant...
May 15, 2025
Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans
He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and...
May 13, 2025
Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera
He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on...
May 9, 2025
BioVenture VoiCes Episode 18: Playground Global's Jory Bell
Jory Bell shares the details of his expansive educational background and early career, which included being a product designer at Apple...
May 4, 2025
At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration
He describes the goals of Swiss Biotech Day, explains how the Swiss biotech sector is funded more by private investment than perhaps...
May 4, 2025
Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma
He describes the history of Nextech, including being an early investor in Blueprint Medicines and Peloton Therapeutics, and discusses the...
May 2, 2025
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research...
Apr 16, 2025
Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why
Dr. Schlessinger describes how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop...
Apr 10, 2025
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover
They discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs....
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Catherine Novack and Debanjana Chatterjee share their take on biotech and comment on companies they cover
They discusses the macro and regulatory factors that have affected the sector so strongly, and comment on Wave, Korro, ProQr, Capricor,...
Apr 9, 2025
HSBC Innovation Banking: Q1 2025 Venture Numbers for Healthcare
HSBC's Jonathan Norris shares an update on Q1 venture numbers for healthcare, and how the venture side of the sector is holding up in...
Apr 4, 2025
Analyst Thursdays: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space
He shares his take on biotech and discusses argenx, Immunovant, AnaptysBio, Apogee, Dianthus, and Viridian.
Apr 3, 2025
Anglo Nordic Life Science Conference: The CEO of Cure Parkinson's talks about their work, and participating in the International Linked Clinical Trials Initiative
CEO Helen Matthews describes the types of medicines they are supporting for clinical trials (including Ambroxol and GLP-1s), and folding...
Apr 3, 2025
Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office
He describes his background in life sciences investing and shares his take on the current state of the sector.
Apr 2, 2025
State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies
He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment,...
Mar 26, 2025
State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics
She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its...
Mar 26, 2025
State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more
She describes the efforts that government is making to support medical research in the area, shares her thoughts on competition in...
Mar 26, 2025
Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers
He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.
Mar 18, 2025
From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle...
Mar 14, 2025
.png){kind=logo}
